CytoDyn Announces Abstract that Highlights Leronlimab’s Potential in Mediating ART-Free Viral Control in Infant Rhesus Macaques Oct 07, 2024 11:05am EDT Press Release
CytoDyn Engages Syneos Health as CRO For Its Phase II Oncology Trial Oct 04, 2024 8:30am EDT Press Release
CytoDyn Announces Preliminary Findings in Study with SMC Laboratories Sep 24, 2024 8:30am EDT Press Release
CytoDyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal Cancer Aug 12, 2024 8:30am EDT Press Release
CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024 Jun 27, 2024 8:30am EDT Press Release
